We’re on a mission to educate people on the importance of checking their blood pressure regularly. Why? Because raised BP is the number one cause of preventable death worldwide.
May Measurement Month is a global blood pressure screening awareness campaign, launched in 2017 by our founding organisation, the International Society of Hypertension.
Our aim is to highlight the importance of measuring your blood pressure (BP) and to raise awareness of the dangers posed by elevated BP and hypertension. Our target is to increase the numbers of participants aged 18+ who are regularly getting their BP checked and to give people the tools to understand how this information can contribute to your knowledge about your individual health. MMM also provides diet and lifestyle advice to those with BP in the hypertensive range and to facilitate improved follow up for sufferers.
On a broader level, MMM uses the data on inadequately treated hypertension to motivate governments to improve BP screening facilities and reduce the huge global burden of disease and death caused by raised BP.
Since 2017, volunteers in more than 100 countries have screened people in cities, towns, and rural villages as part of the largest FREE public blood pressure screening programme in the world. All participants discovered their blood pressure, and anyone who registered as hypertensive was given advice about what they need to do next.
May Measurement Month will take place between 01 May – 31 July 2024 and builds on the WHL’s established World Hypertension Day (held on 17 May each year) with volunteer health professionals at local screening sites, in more than 90 countries.
Professor Neil Poulter, Former ISH President (2016 -2018), and Chief Investigator of MMM, stated:
“Even with increased threats to public health this last year, raised blood pressure remains the biggest single contributing risk factor for global death and the worldwide burden of disease. We want May Measurement Month to increase public understanding, and help save lives that need not be lost ”
Professor Neil Poulter FMedSci
Professor of Preventive Cardiovascular Medicine, Imperial College London, London, United Kingdom
Neil qualified at St Mary’s Hospital in 1974, following which, he trained in General medicine. He spent five years in Kenya co-ordinating a collaborative hypertension research programme at the Wellcome Trust Research Laboratories in Nairobi. In 1985 he gained an MSc in Epidemiology with distinction at the London School of Hygiene and Tropical Medicine. In 1997 he was appointed Professor of Preventive Cardiovascular Medicine at Imperial College London. In 2008, Neil was elected as one of the inaugural Senior Investigators of the NIHR and as a fellow of the Academy of Medical Sciences the following year, in 2009. He held the position of President of the British Hypertension Society from 2003-2005 and also President of the International Society of Hypertension from 2016-2018.
An Honorary Consultant Physician and Epidemiologist at the Peart-Rose (CVD Prevention) Clinic based at Hammersmith Hospital, London, Neil is also Co-Pl of the WHO Oral Contraceptive case-control Study at University College London Medical School. He is currently co-Director of the International Centre for Circulatory Health and Director of the Imperial Clinical Trials Unit and has also held a senior management role in several international trials including the ASCOT, ADVANCE, EXSCEL, DEVOTE LEADER and CREOLE trials. Neil has published over 650 papers in peer-reviewed medical journals, including co-authoring several sets of national and international guidelines and has been identified as being among the top 1% most cited academics in clinical medicine in 2014 (Thomson Reuters Highly Cited Researcher report) and among the top 0.1% most cited researcher between 2008-2018 (Web of Science Group Highly Cited Researcher 2019 and 2020 report). Neil is the Chief Investigator of the May Measurement Month.
Professor Markus Schlaich
President, High Blood Pressure Research Council of Australia
Markus Schlaich is a renal physician and a European Society of Hypertension (ESH) accredited hypertension specialist. He is an International Society of Hypertension (ISH) Fellow and has been on the Executive Committee of the ISH from 2018-2020 acting as Treasurer and Chair of the Asia-Pacific Regional Advisory Group. He currently serves on the Management Board of the global ISH May Measurement Month campaign. Markus is President of the High Blood Pressure Research Council of Australia and a Trustee of the Foundation for High Blood Pressure Research.
Markus has a strong background in clinical research with a focus on the pathophysiology of hypertension, involvement of the kidneys, and hypertension mediated organ damage. He has a specific interest in treatment modalities targeting the sympathetic nervous system and is a founding member of the ESH Working Group on Interventional Treatment of Hypertension. For his work he received the Björn Folkow Award from the ESH and the Arthur C. Corcoran Award from the AHA Hypertension Council, both in 2021. He has authored more than 400 articles and book chapters in peer reviewed journals and serves on the Editorial Board of Hypertension and Journal of Hypertension.
Professor George S. Stergiou, MD, FRCP
Professor of Medicine & Hypertension
Hypertension Center STRIDE-7 (EU), Third University Dept. of Medicine, Sotiria Hospital, Athens.
George is the Chairman of the European Society of Hypertension (ESH) Working Group on blood pressure (BP) Monitoring & Cardiovascular Variability as well as the Chairman of STRIDE BP International Organization on BP measurement methodology and technology www.stridebp.org. He is the World Hypertension League Special Envoy for BP Measurement and an ISO Committee Member on BP monitoring equipment. George is also an Executive Committee member of the International Pediatric Hypertension Association. His research work has focused on BP monitoring methodology, technology development and validation; Hypertension diagnostics; Hypertension epidemiology, control; Pediatric hypertension; Antihypertensive drug action. George has authored 350 PubMed articles and supervised 25 MD theses (h-index 74;Google Scholar citations 45,000). George is also an International Society Hypertension (ISH) Council member.
Professor Alta Schutte PhD FRSSAf FESC ISHF
Professor of Cardiovascular Medicine, University of New South Wales, Australia
Alta Schutte is Professor of Cardiovascular Medicine and Principal Theme Lead of Cardiac, Vascular and Metabolic Medicine at the University of New South Wales, and The George Institute for Global Health in Sydney, Australia. She is also Honorary Professor at the University of the Witwatersrand and the North-West University, South Africa.
Alta’s research interest is the early detection, prevention and effective management of hypertension, where she has led many population and clinical studies, such as the SAfrEIC, POWIRS, and African-PREDICT studies. In 2008 she was the Founding Director of the Hypertension in Africa Research Team (HART) and established the Medical Research Council Unit for Hypertension and Cardiovascular Disease in South Africa in 2015. She served as President of the Southern African Hypertension Society from 2014 to 2016. Since relocating to Australia in 2020 she leads projects focused on improved blood pressure monitoring and blood pressure control.
Alta is an invited author of the Lancet Commission on Hypertension, and of the World Health Organization’s Technical Specifications Report for Automated Non-Invasive Blood Pressure Measuring Devices. She is an Executive Board member of STRIDE BP, an international scientific non-profit organization with the mission of improving the accuracy of blood pressure measurement and diagnosis of hypertension. Since 2017 she contributed to the establishment of May Measurement Month and continues to contribute to the global awareness campaign as a Trustee.
She was President of the International Society of Hypertension (2018-2020) during which time she initiated the development of the 2020 ISH Global Hypertension Practice Guidelines for low and high resource settings.
Alta has contributed to over >400 publications in the field of hypertension (Google H-index 65, >75,000 citations) and ranks in the top 0.019% of 250,197 authors in the field ‘blood pressure (BP)’ (Expertscape) and #15 worldwide when ranked by FWCIs (SciVal) in the Cluster “Hypertension; BP”.
Alta is associated Editor of Hypertension, Hypertension Research and the European Journal of Preventive Cardiology, and editorial board member of all major hypertension journals.
Dr Thomas Beaney MSc MRCP MRCGP
Academic General Practitioner, Imperial College London, United Kingdom
Thomas is a GP and Clinical Research Fellow in the Department of Primary Care and Public Health at Imperial College London. He has been part of the May Measurement Month campaign since 2017 as lead statistician.
Thomas studied Natural Sciences at the University of Cambridge before qualifying in Medicine at Imperial College London in 2013 and completing clinical training as a GP in 2021. In 2015 he was awarded a National Institute for Health Research scholarship to complete an MSc in Medical Statistics at the London School of Hygiene and Tropical Medicine, graduating with Distinction. His research focuses on hypertension and cardiovascular disease epidemiology, global and digital health and health services research. Thomas is currently completing a PhD at Imperial College exploring patterns of multimorbidity using machine learning approaches, funded by the Wellcome Trust.
Managing Director of Virtual IT, London, United Kingdom
David is a businessman from a medical family and with roots in the developing world. In his day job, he is the Managing Director of Virtual IT, an IT managed services provider based in London, UK as well as serving as Chairman and Board Director respectively for two family businesses based in Kenya – Eldama Technologies Limited another IT services business and Serenity Spa, Kenya’s leading health and beauty spas with three branches location around Nairobi. In addition to Virtual / Eldama / Serenity, David serves on the board and is the Chairman of the Governance Committee of Cim Finance Limited in Mauritius, and also chairs the board of Cim’s Kenya subsidiary, Aspira. He is also an advisor to Enasoit Ranch Limited, a nature conservancy based in Laikipia, Kenya.
David’s background includes a number of entrepreneurial technology start ups, including AccessKenya Group Limited, Kenya’s leading corporate internet service provider which was listed on the Nairobi Stock Exchange prior to being sold to a subsidiary of Japan’s NTT Corporation and LCR Telecom Group, a telecom services company which was sold to a NASDAQ listed group. David was a founder of both business and respectively Deputy Chairman and Group CEO. Prior to these businesses, he worked for McKinsey & Co. David has a Law degree from Oxford University and an MBA from Harvard Business School.